The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 27, 2025

Filed:

Jan. 13, 2022
Applicant:

Syz Cell Therapy Co., Guangdong, CN;

Inventors:

Xiangjun Zhou, Guangdong, CN;

Jin Li, Guangdong, CN;

Yanyan Han, Guangdong, CN;

Dongyun Wu, Guangdong, CN;

Junyun Liu, Guangdong, CN;

Longqing Tang, Guangdong, CN;

Ran Tao, Guangdong, CN;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 35/14 (2015.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/14 (2013.01); A61K 40/11 (2025.01); A61K 40/424 (2025.01); A61K 40/4266 (2025.01); A61K 40/4269 (2025.01); A61K 40/428 (2025.01); A61K 45/06 (2013.01); C12N 5/0639 (2013.01); C12N 2501/998 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1121 (2013.01);
Abstract

The present invention provides a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual are provided. Methods of preparing the activated T cells, methods of monitoring the treatment, and methods of cloning tumor-specific T cell receptors are further disclosed. An isolated population of cells comprising the activated T cells, as well as compositions and kits useful for cancer immunotherapy are also provided.


Find Patent Forward Citations

Loading…